Products for Research Use Only
RegisterLogin

YD23

CAT: 0804-HY-153361-01Size: 1 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-153361-01Size:1 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
YD23 is a selective SMARCA2 PROTAC degrader with DC50 values of 64 nM and 297 nM in H1792 cells and H1975 cells. YD23 induces degradation of SMARCA2, which is synthetic lethal to SMARCA4. YD23 reduces chromatin accessibility only in SMARCA4 deficient cells, including cell cycle and cell growth regulatory genes. YD23 selectively inhibits growth of SMARCA4 mutant lung cancer cells. YD23 has potent tumor growth inhibitory activity in SMARCA4-mutant xenografts. YD23 can be used for the study of non-small cell lung cancer (NSCLC) (Pink: SMARCA2 ligand ; Blue: CRBN ligand (HY-41547) ; Black: Linker (HY-175566) )[2].
CAS Number
2951015-29-3
UNSPSC
12352005
Target
Epigenetic Reader Domain; PROTACs
Type
Reference compound
Related Pathways
Epigenetics; PROTAC
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/yd23.html
Purity
98.80
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
O=C1N(C2CCC(NC2=O)=O)C(C3=C1C=CC=C3NCCOCCOC4=C(F)C=C(CN5CCN(C6=C(N)N=NC(C7=C(O)C=CC=C7)=C6)CC5)C=C4)=O
Molecular Formula
C38H39FN8O7
Molecular Weight
738.76
References & Citations
[1]Kotagiri S, et al. Novel SMARCA2 degrading bifunctional molecules as therapeutics in SMARCA4 mutant lung cancer[J]. Cancer Research, 2023, 83 (7_Supplement) : 1138-1138. |[2]Kotagiri S, et al. Enhancer reprogramming by novel SMARCA2 degrading PROTACs underlies therapeutic utility in SMARCA4 mutant tumors[J]. Cancer Research, 2023, 83 (7_Supplement) : 6289-6289.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
Cereblon

Alternative Products

CatalogName
GTR19231281-01YD23
sc-135589TRIM52 (3-YD23)

Popular Products